Gilead Sciences, Inc. $GILD Shares Purchased by MCF Advisors LLC

MCF Advisors LLC boosted its stake in Gilead Sciences, Inc. (NASDAQ:GILD) by 63.5% during the fourth quarter, Holdings Channel.com reports. The fund owned 14,663 shares of the biopharmaceutical company’s stock after purchasing an additional 5,695 shares during the quarter. MCF Advisors LLC’s holdings in Gilead Sciences were worth $1,800,000 at the end of the most recent reporting period.

A number of other institutional investors have also recently added to or reduced their stakes in the stock. Ares Financial Consulting LLC acquired a new stake in Gilead Sciences during the 4th quarter worth $28,000. Financial Consulate Inc. boosted its stake in Gilead Sciences by 85.8% during the 4th quarter. Financial Consulate Inc. now owns 236 shares of the biopharmaceutical company’s stock worth $29,000 after purchasing an additional 109 shares during the last quarter. North Star Investment Management Corp. boosted its stake in Gilead Sciences by 54.8% during the 4th quarter. North Star Investment Management Corp. now owns 243 shares of the biopharmaceutical company’s stock worth $30,000 after purchasing an additional 86 shares during the last quarter. BOCHK Asset Management Ltd acquired a new stake in Gilead Sciences during the 4th quarter worth $31,000. Finally, Godfrey Financial Associates Inc. acquired a new stake in Gilead Sciences during the 4th quarter worth $34,000. Institutional investors and hedge funds own 83.67% of the company’s stock.

Wall Street Analysts Forecast Growth

GILD has been the topic of several recent research reports. Wall Street Zen cut shares of Gilead Sciences from a “strong-buy” rating to a “hold” rating in a research note on Saturday, May 9th. Cantor Fitzgerald lowered their target price on shares of Gilead Sciences from $155.00 to $115.00 and set an “overweight” rating on the stock in a research note on Friday, April 10th. Barclays initiated coverage on shares of Gilead Sciences in a research note on Friday, February 20th. They set an “equal weight” rating and a $155.00 target price on the stock. The Goldman Sachs Group lifted their target price on shares of Gilead Sciences from $125.00 to $130.00 and gave the stock a “neutral” rating in a research note on Friday, April 17th. Finally, Sanford C. Bernstein reaffirmed an “outperform” rating and set a $160.00 target price on shares of Gilead Sciences in a research note on Wednesday, February 11th. Twenty-six analysts have rated the stock with a Buy rating and three have given a Hold rating to the stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $156.93.

Insider Activity

In other news, CFO Andrew D. Dickinson sold 3,000 shares of the business’s stock in a transaction dated Friday, May 15th. The shares were sold at an average price of $132.27, for a total transaction of $396,810.00. Following the transaction, the chief financial officer owned 173,191 shares of the company’s stock, valued at approximately $22,907,973.57. The trade was a 1.70% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Daniel Patrick O’day sold 15,000 shares of the business’s stock in a transaction dated Monday, June 1st. The shares were sold at an average price of $131.46, for a total transaction of $1,971,900.00. Following the transaction, the chief executive officer directly owned 617,567 shares in the company, valued at approximately $81,185,357.82. The trade was a 2.37% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last quarter, insiders have sold 68,000 shares of company stock valued at $9,047,570. 0.30% of the stock is currently owned by insiders.

Gilead Sciences News Summary

Here are the key news stories impacting Gilead Sciences this week:

• Positive Sentiment: Citi and Scotiabank both reiterated bullish views on Gilead, with each firm maintaining a Buy rating, which can support investor confidence in the stock. Gilead Sciences (GILD) Receives a Buy from Citi
• Positive Sentiment: Gilead highlighted progress on lenacapavir in South Africa, where the government and Global Fund are accelerating access to the HIV prevention drug, reinforcing the company’s growth story in HIV. Gilead Applauds Collaborative Efforts to Launch Lenacapavir for HIV Prevention in South Africa
• Positive Sentiment: Gilead and Lakefront completed the acquisition of Ouro Medicines, expanding the inflammation/autoimmune pipeline around gamgertamig, a potential first-in-class T cell engager. Gilead Sciences and Lakefront Complete Acquisition of Ouro Medicines to Further Expand Inflammation Pipeline
• Positive Sentiment: Gilead’s inclusion in a list of “best quality growth stocks” may add to the market’s view that the company remains a high-quality large-cap healthcare name. 5 Best Quality Growth Stocks to Buy
• Neutral Sentiment: Industry-wide biopharma M&A remains active, and Gilead was mentioned among the sector’s deal-making leaders, which keeps takeover speculation and pipeline deal optionality in focus. Gilead, Merck, Eli Lilly Lead $106 Billion Biopharma Takeover Wave In 2026
• Neutral Sentiment: Gilead also reported a clinical milestone in its IDEAL PBC trial, which could become a future catalyst if the study continues to progress positively. Gilead’s IDEAL PBC Trial Reaches Key Milestone, Setting Up a New Liver Disease Catalyst

Gilead Sciences Trading Down 0.0%

Shares of GILD stock opened at $129.16 on Friday. The company’s 50-day moving average price is $134.38 and its 200-day moving average price is $134.31. The company has a current ratio of 1.97, a quick ratio of 1.77 and a debt-to-equity ratio of 0.89. The stock has a market cap of $160.36 billion, a price-to-earnings ratio of 17.60 and a beta of 0.31. Gilead Sciences, Inc. has a twelve month low of $104.46 and a twelve month high of $157.29.

Gilead Sciences (NASDAQ:GILD) last announced its quarterly earnings results on Thursday, May 7th. The biopharmaceutical company reported $2.03 earnings per share for the quarter, beating the consensus estimate of $1.91 by $0.12. The firm had revenue of $6.96 billion for the quarter, compared to analysts’ expectations of $6.91 billion. Gilead Sciences had a net margin of 30.99% and a return on equity of 48.19%. The company’s revenue was up 4.4% compared to the same quarter last year. During the same quarter in the previous year, the company posted $1.81 EPS. Gilead Sciences has set its FY 2026 guidance at -1.050–0.650 EPS. As a group, equities analysts predict that Gilead Sciences, Inc. will post -0.79 earnings per share for the current year.

Gilead Sciences Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Monday, June 29th. Stockholders of record on Monday, June 15th will be given a dividend of $0.82 per share. The ex-dividend date of this dividend is Monday, June 15th. This represents a $3.28 annualized dividend and a dividend yield of 2.5%. Gilead Sciences’s payout ratio is presently 44.69%.

Gilead Sciences Profile

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.